Abstract: One embodiment of the present disclosure is a method of creating metadata during object development. The method comprises receiving a change to an object during its development that results in a changed version of the object, identifying information about the change, and creating metadata comprising the information about the change. The information about the change may include a unique instance identifier identifying and unique to the changed version of the object. As an object is changed multiple times during development, the created metadata may include a series of information segments each relating to a particular change and each uniquely identified by its unique instance identifier. The information about the change may also include, as examples, an identification of a unique instance identifier of a prior version of the object, the time of the change to the object, and/or identification of the software used to make the change.

Abstract: One embodiment of the present disclosure is a method of creating metadata during object development. The method comprises receiving a change to an object during its development that results in a changed version of the object, identifying information about the change, and creating metadata comprising the information about the change. The information about the change may include a unique instance identifier identifying and unique to the changed version of the object. As an object is changed multiple times during development, the created metadata may include a series of information segments each relating to a particular change and each uniquely identified by its unique instance identifier. The information about the change may also include, as examples, an identification of a unique instance identifier of a prior version of the object, the time of the change to the object, and/or identification of the software used to make the change.

Abstract: The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with other drugs to treat cardiovascular diseases such as, but not limited to, muscle atrophy, cardiac hypertrophy, heart failure, and primary pulmonary hypertension.

Abstract: The present invention provides certain substituted 1,4-dihydropyridine compounds, including pure enantiomeric forms and pharmaceutical formulations thereof. These compounds provide for elevation of ?-MyHC protein levels and ?-MyHC mRNA levels, and most frequently these same compounds provide simultaneous lowering of ?-MyHC protein levels and ?-MyHC mRNA levels. Thus, these compounds may be used alone or in conjunction with other drugs to treat heart failure.

Abstract: The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with other drugs to treat cardiovascular diseases such as, but not limited to, muscle atrophy, cardiac hypertrophy, heart failure, and primary pulmonary hypertension.

Abstract: The present invention provides certain substituted 1,4-dihydropyridine compounds, including pure enantiomeric forms and pharmaceutical formulations thereof. These compounds provide for elevation of ?-MyHC protein levels and ?-MyHC mRNA levels, and most frequently these same compounds provide simultaneous lowering of ?-MyHC protein levels and ?-MyHC mRNA levels. Thus, these compounds may be used alone or in conjunction with other drugs to treat heart failure.

Abstract: The present invention provides certain substituted 1,4-dihydropyridine compounds, including pure enantiomeric forms and pharmaceutical formulations thereof. These compounds provide for elevation of ?-MyHC protein levels and ?-MyHC mRNA levels, and most frequently these same compounds provide simultaneous lowering of ?-MyHC protein levels and ?-MyHC mRNA levels. Thus, these compounds may be used alone or in conjunction with other drugs to treat heart failure.

Abstract: A method, apparatus and computer-readable medium for converting messages includes stations coupled to facsimile devices and to client machines by a network to allow users at the client machines to communicate with users at the facsimile devices. In addition, the stations include processors for extracting information from messages sent by users at the facsimile devices and received by the stations, using the extracted information to convert the messages, and sending the converted messages through the network to the users at the client machines.

Abstract: A method, apparatus and computer-readable medium for converting messages includes stations coupled to facsimile devices and to client machines by a network to allow users at the client machines to communicate with users at the facsimile devices. In addition, the stations include processors for extracting information from messages sent by users at the facsimile devices and received by the stations, using the extracted information to convert the messages, and sending the converted messages through the network to the users at the client machines.